R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

... that in the TASKi3 Phase 2b clinical trial in rheumatoid arthritis (RA) patients who had failed to respond ... ----- ------ * RAMRIS is a rheumatoid arthritis scoring system utilizing magnetic ... R788 TASKi3 Phase 2b clinical trial of R788 in rheumatoid arthritis, the Company's plans for further ...

Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial

... produced significant clinical improvement in rheumatoid arthritis (RA) patients in the recently completed ... R788 TASKi2 Phase 2b clinical trial of R788 in rheumatoid arthritis, the Company's plans for further ... in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well ...

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

... for the treatment of moderate-to-severe, active rheumatoid arthritis (RA), active and progressive psoriatic ... anti-TNF therapy for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing ... active RA, active PsA and active AS. In Phase 3 rheumatoid arthritis trials, SIMPONI was shown to be ...

New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients

... of patients with moderately to severely active rheumatoid arthritis (RA) who had prior treatment with ... "Golimumab has shown promise in the treatment of rheumatoid arthritis patients who have previously ... and provides hope for people struggling with rheumatoid arthritis." Regardless of the particular ...

Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients

... efficacy of ACTEMRA across a broad range of rheumatoid arthritis patient populations - NUTLEY, ... study demonstrated that a greater proportion of rheumatoid arthritis (RA) patients treated with ACTEMRA(R) ... in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and ...

CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas

... such as CEL-2000 being developed as a vaccine for rheumatoid arthritis, can also be used with comparable ... important for an immunotherapy aimed at rheumatoid arthritis, since these cytokines cause much of the damage seen in rheumatoid arthritis patients, and has important ...

Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients

... of structural damage to joints in patients with rheumatoid arthritis (RA). The study also showed that ... in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and ... target IL-6 in patients with RA. About rheumatoid Arthritis RA is a progressive, systemic ...

Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis

... 2 proof-of-concept trial in patients with active rheumatoid arthritis (RA) receiving methotrexate ... important and novel treatment option for rheumatoid arthritis and potentially other inflammatory ... companion Phase 2 study." About MDX-1100 in rheumatoid Arthritis MDX-1100 is a fully human antibody ...

Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)

... for adults with moderately to severely active rheumatoid arthritis and moderate to severe Crohn's disease, ... from the UCB partnership with OXO(R) -- rheumatoid arthritis patients directly involved with UCB and ... self-administration easy for people living with rheumatoid arthritis ATLANTA, May 14 /PRNewswire/ -- ...

Staying One Step Ahead of Osteoporosis

... women and 20 percent men, who were affected by rheumatoid arthritis and under Vitamin D supplementation. ... between a person's age, sex, how long they had rheumatoid arthritis, whether they were taking Vitamin D ... Pegreffi. "We found that women affected by rheumatoid arthritis for more than three years were ...

Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)

... adult patients with moderately to severely active rheumatoid arthritis (RA). As a result of the ... treatment of moderately severe to severe, active rheumatoid arthritis in adult patients who did not respond ... in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and ...

CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients

... was first approved in 1998 for moderate to severe rheumatoid arthritis and has since been used in nearly ... approved for the following indications: rheumatoid arthritis Enbrel in combination with ... for the treatment of moderate to severe active rheumatoid arthritis in adults when the response ...

Rigel's R788 Phase 2a Results Published in Arthritis and Rheumatism

... Rheumatism. The article, entitled, "Treatment of rheumatoid arthritis with a syk kinase inhibitor: ... TASKi1, which enrolled 189 patients with active rheumatoid arthritis (RA) already taking methotrexate for ... in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well ...

CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years

... long-term benefit in relieving symptoms of rheumatoid arthritis (RA) through 100 weeks. Another ... Safety of cerTolizumab pegol - 4 Weekly dosAge in rheumatoid arthritis, Study O11) phase III study, 220 adult ... ACR50 and ACR70 responder rates. About rheumatoid Arthritis ...

New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients

... in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and ... target IL-6 in patients with RA. About rheumatoid Arthritis rheumatoid arthritis is a progressive, systemic autoimmune ...

ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments

... from the debilitating and painful effects of rheumatoid arthritis (RA) achieved significant improvements ... in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and ... target IL-6 in patients with RA. About rheumatoid Arthritis ...

Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis

... CVM ) announced today that it presented new rheumatoid arthritis data at the Marcus Evans conference on ... or retards the permanent tissue damage caused by rheumatoid arthritis in an animal model of the disease. ... some of the same parameters that can be seen in rheumatoid arthritis damage in humans. CEL-2000 was as good ...

New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis

... its unprecedented initiative to find a cure for rheumatoid arthritis, the American College of Rheumatology ... by the Within Our Reach: Finding a Cure for rheumatoid Arthritis campaign. Doctors and scientists from ... RA. About Within Our Reach: Finding a Cure for rheumatoid Arthritis ...

Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City

... cells that can cause tissue damage in rheumatoid arthritis and inflammatory bowel ... for ulcerative colitis and rheumatoid arthritis. Interim data from these trials are ... 1 trials in chronic lymphocytic leukemia and rheumatoid arthritis are ongoing with data expected in ...

ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies

... suffer the chronic and debilitating effects of rheumatoid arthritis (RA) -- despite treatment with current ... target IL-6 in patients with RA. About rheumatoid Arthritis rheumatoid arthritis is a progressive, systemic autoimmune ...

Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis

... as the First-line Option in the treatment of rheumatoid arthritis of Early onset (GO-BEFORE), MTX-naive ... of response, improving multiple aspects of rheumatoid arthritis and leading to significant decreases in ... of hepatitis B, and other serious events. About rheumatoid Arthritis ...

ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354

... is associated with inflammatory diseases such as rheumatoid arthritis. With the dosing of the first ... certain autoimmune diseases such as rheumatoid arthritis (RA), as well as other inflammatory ... the migration of inflammatory cells leading to rheumatoid arthritis and subsequently joint destruction. ...

Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis

... multiple inflammatory disease indications such as rheumatoid arthritis, inflammatory bowel disease and ... Americans with ulcerative colitis. About rheumatoid Arthritis According to the American College of ... more than two million Americans suffer from rheumatoid arthritis (RA), a chronic autoimmune disease that ...

New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients

... of structural damage to joints in patients with rheumatoid arthritis (RA), a critical measure ... 2008, ACTEMRA was approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis ... IL-6 inhibition in patients with RA. About rheumatoid Arthritis ...

Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing

... in inflammatory indications such as rheumatoid arthritis - NUTLEY, N.J., April 15 /PRNewswire/ ... in treating inflammatory diseases such as rheumatoid arthritis. Through this acquisition, Roche's ... efforts in debilitating diseases such as rheumatoid arthritis." Michael Moore, Chief Executive of ...

U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older

... for use concomitantly with other biologic rheumatoid arthritis (RA) therapy, such as anakinra. This ... Polyarticular JIA (64 percent; 20 percent were rheumatoid factor (RF) positive) and Systemic JIA with ... (JIA) JIA -- also commonly known as Juvenile rheumatoid Arthritis (JRA) -- is the most common chronic ...

Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis

... damage and reducing the signs and symptoms of rheumatoid arthritis during the first year of treatment are ... The new report entitled rheumatoid Arthritis: Competitive, Crowded Market Sets the ... as the clinical gold standard treatment for rheumatoid arthritis. While some therapies in development ...

International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet

... diminish the painful and debilitating effects of rheumatoid arthritis," said Josef Smolen, M.D., lead ... target IL-6 in patients with RA. About rheumatoid Arthritis rheumatoid arthritis is a progressive, systemic autoimmune ...

Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis

... years of clinical trial experience beginning with rheumatoid arthritis patients. It was approved for moderate to severe rheumatoid arthritis in 2002, psoriatic arthritis in 2005, ... to that seen in HUMIRA clinical trials for rheumatoid arthritis (RA). The most commonly reported ...

Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)

... we can empower and motivate people with rheumatoid arthritis to consult with their rheumatologist ... in their young- to mid-adult years. Juvenile rheumatoid arthritis is the most common form of arthritis in ... manufactures ENBREL, which may be used to treat rheumatoid arthritis, ...

Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342

... leukemia (CLL) and the other for rheumatoid arthritis. MDX-1342 is a fully human antibody ... of MDX-1342. The IND for the treatment of rheumatoid arthritis is for a randomized, single-dose, ... is expected to enroll up to 90 patients with rheumatoid arthritis. This trial is designed to evaluate the ...

Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis

... seeking approval to treat rheumatoid arthritis - NUTLEY, N.J., Nov. 21 /PRNewswire/ ... and symptoms in adults with moderate to severe rheumatoid arthritis (RA). "The filing for ACTEMRA ... or any observed impact on liver function. About rheumatoid Arthritis ...

Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)

... independence and sleep quality in adult rheumatoid arthritis (RA) patients who have had an ... in adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to ... Enbrel(R), Humira(R), Remicade(R)) to treat rheumatoid arthritis (RA). ORENCIA should not be taken with ...

Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis

... study that showed that Trubion's TRU-015 for rheumatoid arthritis (RA) provided statistically significant ... of Wyeth (NYSE: WYE ), for the treatment of rheumatoid arthritis. These data will be presented during ... by potential products in clinical trials. About rheumatoid Arthritis RA is a chronic disease, mainly ...

Two Pivotal Phase III Studies for Roche's ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms

... in April 2006, additional indications for rheumatoid arthritis and systemic-onset juvenile idiopathic ... in some patients treated with ACTEMRA. About rheumatoid Arthritis rheumatoid arthritis is a progressive, systemic autoimmune ...

Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis

... With ongoing studies for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing ... With ongoing studies for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing ... innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, ...

New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings

... With ongoing studies for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing ... With ongoing studies for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing ... innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, ...

CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year

... joint damage in patients with active rheumatoid arthritis (RA). Also, CIMZIA combined with ... (certolizumab pegol) in the treatment of rheumatoid arthritis. The RAPID clinical trial program ... less progression of joint damage.(2) About rheumatoid Arthritis ...

Abbott's m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award

... ), the first human monoclonal antibody drug for rheumatoid arthritis, won the award. "At Abbott we're in ... adult patients with moderately to severely active rheumatoid arthritis. HUMIRA is indicated for reducing the ... seen in the placebo-controlled clinical trials in rheumatoid arthritis (HUMIRA vs. placebo) were injection ...

EntreMed Raises $20 Million to Support Clinical Development Program

... to fund IND-directed activities for Panzem(R) in rheumatoid arthritis and our Aurora-angiogenesis inhibitor ... is also in preclinical development for rheumatoid arthritis, and ENMD-2076, a dual-acting ... treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed ...